Evidence that pioglitazone, metformin and pentoxifylline are inhibitors of glycation

Clinica Chimica Acta

Volumn 301, Issue 1-2, 2000, Pages 65-77

  Rahbar, Samuel ^a   Natarajan, Rama ^a   Yerneni, Kirankumar ^a   Scott, Stephen ^a   Gonzales, Noe ^a   Nadler, Jerry L ^b  

^a Department of Diabetes   (United States)

^b UNIVERSITY OF VIRGINIA   (United States)

Author keywords

AGEs; Glycation; Glycation inhibitors; Metformin; Pentoxifylline; Pioglitazone

Indexed keywords

ADVANCED GLYCATION END PRODUCT; METFORMIN; PENTOXIFYLLINE; PIOGLITAZONE;

ARTICLE; DIABETES MELLITUS; DRUG ACTIVITY; DRUG EFFECT; DRUG MECHANISM; DRUG POTENCY; DRUG STRUCTURE; GLYCATION; HUMAN; PERIPHERAL VASCULAR DISEASE; PRIORITY JOURNAL;

ENZYME-LINKED IMMUNOSORBENT ASSAY; GLYCOSYLATION END PRODUCTS, ADVANCED; HEMOGLOBIN A, GLYCOSYLATED; HUMAN; HYPOGLYCEMIC AGENTS; METFORMIN; PENTOXIFYLLINE; SUPPORT, U.S. GOV'T, P.H.S.; THIAZOLES;

EID: 0033795141     PISSN: 00098981     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0009-8981(00)00327-2     Document Type: Article

References (50)

1. Bucala R., Cerami A. Advanced glycosylation: chemistry, biology and implications for diabetes and aging. Adv Pharmacol. 23:1992;1-33.
2. Bucala R., Makita Z., Koschinsky T., Cerami A., Vlassara H. Lipid advanced glycation pathway for lipid oxidation. Proc Natl Acad Sci USA. 90:1993;6434-6438.
3. Bucala R., Model P., Cerami A. Modification of DNA by reducing sugars: a possible mechanism for nucleic acid aging and age-related dysfunction in gene expression. Proc Natl Acad Sci USA. 81:1984;105-109.
4. Yan H., Harding J.J. Inactivation and loss of antigenicity of esterase by sugars and steroid. Biochim Biophys Acta. 1454:1999;183-190.
5. Boel E., Selmer J., Flodgaard H.J., Jensen T. Diabetic late complications: will aldose reductase inhibitors or inhibitors of advanced glycosylation end products formation hold promise? J Diabetes Complications. 9:1995;104-129.
6. Silbiger S., Crowley S., Shan Z., Brownlee M., Satriano J., Scholondorff D. Nonenzymatic glycation of mesangial matrix and prolonged exposure of mesangial matrix to elevated glucose reduces collagen synthesis and proteoglycan charge. Kidney Int. 43:1993;853-864.
7. The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. New Engl J Med. 329:1993;977-986.
8. Makita Z., Bucala R., Rayfield E.J., et al. Reactive glycosylation endproducts in diabetic uremia and treatment of renal failure. Lancet. 343:1994;1519-1522.
9. Koschinsky T., He C.J., Mitsuhaski T., et al. Orally absorbed reactive glycation products (glycotoxins): an environmental risk factor in diabetic nephropathy. Proc Natl Acad Sci USA. 94:1997;6474-6479.
10. Makita Z., Radoff S., Rayfield E.J., et al. Advanced glycosylation end products in patients with diabetic nephropathy. New Eng J Med. 325:1993;836-842.
11. Bucala R., Makita Z., Vega G., et al. Modification of LDL by advanced glycosylation end products contributes to dyslipidemia of diabetes and renal insufficiency. Proc Natl Acad Sci USA. 91:1994;9441-9445.
12. Bailey A.J., Paul R.G., Knott L. Mechanisms of maturation and aging of collagen. Mech Aging Dev. 106:1998;1-56.
13. Vlassara H., Bucala R., Striker L. Pathogenic effects of advanced glycosylation: biochemical, biologic, and clinical implications for diabetes and aging. Lab Invest. 70:1994;138-151.
14. Horie K., Miyata T., Maeda K., et al. Immunohistochemical colocalization of glyoxidation products and lipid peroxidation products in diabetic renal glomerular lesions. J Clin Invest. 100:1997;2995-3004.
15. Matsumoto K., Ikeda K., Horiuchi S., Zhao H., Abraham E.C. Immunohistochemical evidence for increased formation of advanced glycation end products and inhibition by aminoguanidine in diabetic rat lines. Biochem Biophys Res Commun. 241:1997;352-354.
16. Soulis-Liparota T., Cooper M., Pazolgou D., Clark B., Jerums G. Retardation by aminoguanidine of development of albuminuria, mesangial expansion, and tissue fluorescence in streptozocin-induced diabetic rat. Diabetes. 40:1991;1328-1334.
17. Bucala R., Vlassara H. Lipid and lipoprotein modification by advanced glycation end-products: role in atherosclerosis. Exp Physiol. 82:1997;327-337.
18. Baynes J.W., Thorpe S.R. Perspective in diabetes: role of oxidative stress in diabetes complications. A new perspective on an old paradigm. Diabetes. 48:1999;1-9.
19. Onorato JM, Thorpe SR, Baynes JW. Immunohistochemical and ELISA assays for biomarkers of oxidative stress in aging and disease. Ann NY Acad Sci 1999;277-90.
20. McLellan A.C., Thornalley P.J., Benn J., Sonksen P.H. Glyoxalase system in clinical diabetes mellitus and correlation with diabetic complications. Clin Sci. 87:1994;21-29.
21. Phillips S.A., Thornalley P.J. The formation of methylglyoxal from triose phosphates. Investigation using a specific assay for methylglyoxal. Eur J Biochem. 212:1993;101-105.
22. Beisswenger P, Smith K, Howell S, Touchette A, Szwergold B. Accelerated diabetic nephropathy is associated with increased methylglyoxal production [abstract]. Am Diab Assoc, 58th Annual Meeting, #312, Chicago, June 1998.
23. Yim H.S., Kang S.O., Hah Y.C., Chock P.B., Yim M.B. Free radicals generated during the glycation of amino acids by methylglyoxal. J Biol Chem. 270:1995;28228-28233.
24. Takahashi M., Pischetsriedes M., Monier V.M. Isolation, purification, and characterization of amadoriase isoenzymes (fructosyl amine-oxygen oxidoreductase EC 1.5.3) from Aspergillus sp. J Biol Chem. 272:1997;3437-3443.
25. Schmidt A.M., Hasu M., Popov D., et al. Receptor for advanced glycation end products (AGEs) has a central role in vessel wall interactions and gene activation in response to circulating AGE protein. Proc Natl Acad Sci USA. 91:1994;8807-8811.
26. Yan S.D., Stern D., Schmidt A.M. Whats the RAGE, the receptor for advanced glycation end products (RAGE) and the dark side of glucose. Eur J Clin Invest. 27:1997;179-181.
27. Westwood M.E., Argirov O.K., Abordo E.A., Thornalley P.J. Methylglyoxal-modified arginine residues - a signal for receptor-mediated endocytosis and degradation of proteins by monocytic THP-1 cells. Biochim Biophys Acta. 1356:1997;84-94.
28. Schalkwijk C.G., Vermeer M.A., Stehanwer C.D.A., Kopple J.T., Princen H.M.G., Van Hinsbergh V.W.M. Effects of methylglyoxal on the physico-chemical and biological properties of low-density lipoprotein. Biochim Biophys Acta. 1394:1998;187-198.
29. Bucala R., Makita Z., Koschinsky T., Cerami A., Vlassara H. Lipid advanced glycosylation: pathway for lipid oxidation in vivo. Proc Natl Acad Sci USA. 92:1993;6934-6938.
30. Al-Abed Y., Leibich H., Voelter W., Bucala R. Hydroxyalkenal formation induced by advanced glycosylation of low density lipoprotein. J Biol Chem. 271:1996;2892-2896.
31. Requena J.R., Ahmed M.U., Fountain C.W., et al. Carboxymethylethanolamine: a biomarker of phospholipid modification during the Maillard reaction in vivo. J Biol Chem. 272:1997;17473-17479.
32. Khalifa R.G., Baynes J.W., Hudson B.G. Breakthroughs and view: Amadorins: novel post-Amadori inhibitors of advanced glycation end product. Biochem Biophys Res Commun. 257:1999;251-258.
33. Miyata T., Van Ypersele De Strihou C., Kurokawa K., Baynes J.W. Alterations in nonenzymatic biochemistry in uremia: Origin and significance of 'carbonyl stress' in long-term uremic complications. Kidney Int. 55:1999;389-399.
34. Brownlee M., Vlassara H., Kooney A., Ulrich P., Cerami A. Aminoguanidine prevents diabetes-induced arterial wall protein cross-linking. Science. 232:1986;1629.
35. Picard S., Parthasararathy S., Fruebis J., Witztum J.L. Aminoguanidine inhibits oxidative modification of low density lipoprotein protein and the subsequent increase in uptake by macrophage scavenger receptors. Proc Natl Acad Sci USA. 89:1992;6876-6880.
36. Chen H.J.C., Cerami A. Mechanism of inhibition of advanced glycosylation by aminoguanidine in vitro. J Carbohydr Chem. 12:1993;731-742.
37. Corbett J.A., Tilton R.G., Chang K., et al. Aminoguanidine, a novel inhibitor of nitric oxide formation, prevents vascular dysfunction. Diabetes. 41:1992;552-556.
38. Sensi M., Deroci M.G., Celi E.S., et al. D-Lysine reduces the non-enzymatic glycation of proteins in experimental diabetes mellitus in rats. Diabetologia. 36:1993;797-801.
39. Tagaki Y., Kashiwagi A., Tanaka Y., Takayuki A., Kikkawa R., Shigeta T. Significance of fructose-induced protein oxidation and formation of advanced glycation end product. J Diabetes Complications. 9:1995;87-91.
40. McPherson J.D., Shilton B.H., Walton D.J. Role of fructose in glycation and cross-linking of proteins. Biochemistry. 27:1988;1901-1907.
41. Booth A.A., Khalifah R.J., Todd P., Hudson B.G. In vitro kinetic studies of formation of antigenic advanced glycation end products (AGEs). J Biol Chem. 272:1997;5430-5437.
42. Miyata T., Ishikawa S., Asahi K., et al. 2-Isopropylidenehydrozono-4-oxo-thiazolidin-5-ylacetanilide (OPB-9195) treatment inhibits the development of intimal thickening after balloon injury of rat carotid artery: role of glycoxidation and lipoxidation reactions in vascular tissue damage. FEBS Lett. 445:1999;202-206.
43. Rahbar S., Yernini K., Scott S., Gonzales N., Lalezari I. Novel inhibitors of advanced glycation end products. Biochem Biophys Res Commun. 262:1999;651-656.
44. Rahbar S., Nadler J.L. A new rapid method to detect inhibition of Amadori product generated by delta-gluconolactone. Clin Chim Acta. 287:1999;123-130.
45. ε-(Carboxymethyl)lysine protein adduct is a major immunological epitope in proteins modified with advanced glycation end products of the maillard reaction. Biochemistry. 35:1996;8075-8083.
46. Nagaraj R.H., Shipanova I.N., Faust F.M. Protein cross-linking by the maillard reaction. J Biol Chem. 271:1996;19338-19345.
47. Al-Abed Y., Kapurniotu A., Bucala R. Advanced glycation end products: detection and reversal. Methods Enzymol. 309:1999;152-172.
48. Nakamura S., Makita Z., Ishikawa S., et al. Progression of nephropathy in spontaneous diabetic rats is prevented by OPB-9195, a novel inhibitor of advanced glycation. Diabetes. 46:1997;895-899.
49. Iwashima Y., Eto M., Horiuchi S., Sano H. Advanced glycation end product-induced peroxisome proliferator-activated receptor (gene expression in the cultured mesangial cells. Biochem Biophys Res Commun. 264:1999;441-448.
50. Lehninger A.L. In principles of biochemistry. 2nd ed :1990;282 CBS Publishers, New Dehli.